6 active not recruiting, 4 recruiting, 2 completed, 2 withdrawn. 10 Phase 1, 5 Phase 2, 2 Early Phase 1.
Follow Recurrent Gliosarcoma: new trials by email Literature Review of Recurrent Gliosarcoma trials Research Report on Recurrent Gliosarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma Actinium Ac 225 Lintuzumab, Biospecimen Collection, Cemiplimab - Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma | Phase 1 | Not yet recruiting | National Cancer Institute (NCI) | 30 | 2026-12-04 | 2026-06-12 |
| GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma Biospecimen Collection, Bispecific CD80-lgG4Fc-IL-2v Fusion Protein GI-102, Computed Tomography - Glioblastoma, IDH-Wildtype, Progressive Astrocytoma, IDH-Mutant, Grade 4 | Phase 2 | Recruiting | Mayo Clinic | 36 | 2026-08-03 | 2026-10-30 |
| ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial Biospecimen Collection, Echocardiography Test, EGFR Inhibitor ERAS-801 - Glioblastoma, Glioblastoma, IDH-Wildtype | Phase 1 | Recruiting | Jonsson Comprehensive Cancer Center | 50 | 2025-07-28 | 2026-09-18 |
| Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBM Cord Blood-derived Expanded Allogeneic Natural Killer Cells, Resection - Recurrent Gliosarcoma, Recurrent Supratentorial Glioblastoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 25 | 2023-04-28 | 2026-09-04 |
| Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma Biospecimen Collection, Efineptakin alfa, Pembrolizumab - High Grade Astrocytic Tumor, Recurrent Glioblastoma, IDH-Wildtype | Phase 2 | Active not recruiting | Mayo Clinic | 53 | 2023-01-24 | 2026-10-05 |
| Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma Atezolizumab, Cabozantinib - Recurrent Glioblastoma, Recurrent Gliosarcoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 47 | 2022-09-23 | 2026-08-25 |
| Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma or Gliosarcoma Liothyronine, Lomustine, Methimazole - Recurrent Glioblastoma, Recurrent Gliosarcoma | Early Phase 1 | Withdrawn | Emory University | 2021-10-20 | 2022-12-02 | |
| ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent Glioblastoma Akt/ERK Inhibitor ONC201, Radiation Therapy, Resection - Recurrent Glioblastoma, Recurrent Gliosarcoma | Phase 1 | Withdrawn | Jonsson Comprehensive Cancer Center | 2021-05-01 | 2021-05-12 | |
| Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma Mycophenolate Mofetil, Radiation Therapy, Re-resection (as part of standard of care) - Recurrent Glioblastoma, Recurrent Gliosarcoma | Phase 1 | Active not recruiting | University of Michigan Rogel Cancer Center | 68 | 2020-08-05 | 2026-05-14 |
| MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma Oncolytic Adenovirus Ad5-DNX-2401, Therapeutic Conventional Surgery - IDH1 wt Allele, Recurrent Anaplastic Astrocytoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 36 | 2019-02-12 | 2026-09-25 |
| Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM EGFRvIII-CARs - Recurrent Glioblastoma, Recurrent Gliosarcoma | Phase 1 | Terminated | Gary Archer Ph.D. | 2 | 2018-05-30 | 2021-04-05 |
| Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas Carboxylesterase-expressing Allogeneic Neural Stem Cells, Irinotecan, Irinotecan Hydrochloride - Recurrent Anaplastic Astrocytoma, Recurrent Anaplastic Oligoastrocytoma | Phase 1 | Active not recruiting | City of Hope Medical Center | 18 | 2016-04-05 | 2026-05-11 |
| Pembrolizumab in Treating Patients With Recurrent Glioblastoma Laboratory Biomarker Analysis, Pembrolizumab, Pharmacological Study - Recurrent Glioblastoma, Recurrent Gliosarcoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 18 | 2015-04-28 | 2026-09-03 |
| Vaccine Therapy in Treating Patients With Recurrent Glioblastoma Laboratory Biomarker Analysis, Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine - Giant Cell Glioblastoma, Recurrent Glioblastoma | Early Phase 1 | Completed | Mayo Clinic | 20 | 2013-11-27 | 2023-06-28 |
| Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme temozolomide and bevacizumab - Recurrent Glioblastoma Multiforme, Recurrent Gliosarcoma | Phase 2 | Completed | Center for Neurosciences, Tucson | 30 | 2009-04-01 | 2017-03-30 |
| Lonafarnib and Temozolomide in Treating Patients with Glioblastoma Multiforme That is Recurrent or Did Not Respond to Previous Treatment with Temozolomide Lonafarnib, Temozolomide - Malignant Supratentorial Neoplasm, Recurrent Glioblastoma | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 34 | 2004-12-21 | 2024-10-17 |
Gliosarcoma (16) · Glioblastoma (15) · Glioma (4) · Astrocytoma (3) · Brain Neoplasms (1) · Oligodendroglioma (1) · Supratentorial Neoplasms (1)
Neoplasms (16) · Neoplasms by Histologic Type (16) · Neoplasms, Germ Cell and Embryonal (16) · Neoplasms, Glandular and Epithelial (16) · Neoplasms, Nerve Tissue (16) · Neoplasms, Neuroepithelial (16) · Neuroectodermal Tumors (16) · Astrocytoma (12) · Glioma (12) · Brain Diseases (2) · Central Nervous System Diseases (2) · Central Nervous System Neoplasms (2) · Neoplasms by Site (2) · Nervous System Diseases (2) · Nervous System Neoplasms (2)
Specimen Handling (4) · Magnetic Resonance Spectroscopy (3) · Temozolomide (3) · pembrolizumab (3) · Radiotherapy (2) · Surgical Procedures, Operative (2) · Actinium (1) · Bevacizumab (1) · Biopsy (1) · Fluorodeoxyglucose F18 (1) · Irinotecan (1) · Lomustine (1) · Methimazole (1) · Mycophenolic Acid (1) · Photons (1)
M.D. Anderson Cancer Center (5) · Mayo Clinic (3) · Jonsson Comprehensive Cancer Center (2) · Center for Neurosciences, Tucson (1) · City of Hope Medical Center (1) · Emory University (1) · Gary Archer Ph.D. (1) · National Cancer Institute (NCI) (1) · University of Michigan Rogel Cancer Center (1)
United States (14)
Phioanh Nghiemphu (2) · Daniel Landi, MD (1) · David Ashley, MBBS, FRACP, PhD (1) · Frederick F Lang (1) · Ian Parney (1) · Jana L Portnow (1) · Jeffrey J. Olson, MD (1) · Jian L Campian, MD, PhD (1) · Jian L. Campian, MD, PhD (1) · Megan Mantica (1) · Michael A. Badurddoja, MD (1) · Nathan Clarke, MD (1) · Shiao-Pei S Weathers (1) · Shiao-Pei S Weathers, MD (1) · Vinay Puduvalli (1)
PMID 31755915, PMID 34824133, PMID 36274161
P30CA033572 (1), P30CA138292 (1), P50CA190991 (1), P50CA211015 (1), R01CA198076 (1), R01CA279984 (1), R01CA288862 (1), R37CA258346 (1), UM1CA186690 (1)